Cormorant Asset Management, LP has filed its 13F form on May 15, 2024 for Q1 2024 where it was disclosed a total value porftolio of $1.74 Billion distributed in 57 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Moon Lake Immunotherapeutics with a value of $427M, Eye Point Pharmaceuticals, Inc. with a value of $142M, Arcellx, Inc. with a value of $124M, Alpine Immune Sciences, Inc. with a value of $107M, and Bridge Bio Pharma, Inc. with a value of $99M.

Examining the 13F form we can see an increase of $76.3M in the current position value, from $1.66B to 1.74B.

Cormorant Asset Management, LP is based out at Boston, MA

Below you can find more details about Cormorant Asset Management, LP portfolio as well as his latest detailed transactions.

Portfolio value $1.74 Billion
Healthcare: $1.74 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History


  • Portfolio
  • No. of Stocks 57
  • Current Value $1.74 Billion
  • Prior Value $1.66 Billion
  • Filing
  • Period Q1 2024
  • Filing Date May 15, 2024
  • Form Type 13F-HR
  • Activity in Q1 2024
  • New Purchases 18 stocks
  • Additional Purchases 9 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 10 stocks
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.


Stay updated on Cormorant Asset Management, LP with notifications on news.